The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin
Type 2 diabetes is a progressive metabolic disorder, accounting for more than 90% of all cases of diabetes. Treatment strategies target blood glucose reduction and non-glycemic effects that can reduce long-term complications, such as cardiovascular disease. Although metformin is often initially effe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2016-03-01
|
| Series: | Romanian Journal of Diabetes Nutrition and Metabolic Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/rjdnmd-2016-0014 |